Mar 16, 2026 4:30 pm EDT iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Mar 9, 2026 7:00 am EDT iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Feb 10, 2026 4:05 pm EST iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Nov 12, 2025 4:01 pm EST iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Oct 30, 2025 7:00 am EDT iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
Oct 23, 2025 7:00 am EDT iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Oct 21, 2025 7:00 am EDT iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025